The Medical Advisor

Abstract Background: Cancer has historically been defined by genetic alterations driving uncontrolled proliferation. However, metabolic reprogramming is now recognized as a fundamental characteristic of malignant cells that supports survival, proliferation, and interaction with the tumor microenvironment. Recent reviews have conceptualized metabolic alterations as emerging hallmarks of cancer physiology. Objective: We propose a comprehensive set of metabolic hallmarks of cancer , synthesizing recent literature on glucose metabolism, mitochondrial function, metabolite signaling, and metabolic‑immune interactions. Methods: We integrated insights from high‑impact reviews in cancer metabolism (e.g., Cell Metabolism, Molecular Cancer, Frontiers in Oncology) to define ten metabolic hallmarks with mechanistic and clinical relevance. Results: The ten hallmarks include: (1) Aerobic glycolysis; (2) Mitochondrial reprogramming; (3) Lactate accumulation; (4) Metabolic immune suppression; ...

Brain cancer, particularly aggressive forms like glioblastoma multiforme (GBM), remains one of the most formidable challenges in oncology, with limited treatment options, high recurrence rates, and dismal survival prognoses despite advances in surgery, chemotherapy, and radiation.  In recent years, however, a paradigm shift has emerged through the repurposing of established antiparasitic medications—ivermectin and mebendazole—as potential adjunctive therapies. These drugs, long proven safe for human use against parasitic infections, are now drawing attention for their anticancer properties, including the ability to target cancer stem cells, disrupt tumor metabolism, and cross the blood-brain barrier to combat intracranial malignancies.  Drawing from a surge of compelling success stories documented from 2019 (METRICS study) to 2025, this article explores more than 100 real-world case reports of patients achieving remarkable outcomes, such as tumor stabilization, shrinkage, and ...